Biologics Market Growth Demands Quality Science that Can Keep Pace

There is no doubt that the biologics market will continue to grow and evolve, and with that growth comes many new opportunities for pharma and biotech companies and the patients they serve. If our industry continues to make quality a core focus in every aspect of the large molecule drug development process, then we will be able to rise to the demands of innovation and deliver more effective, safer therapies for the individuals that need them most.

Click for full article
Share This

Other Podcasts

Welcome to episode one of the Molecular Moments podcast! On this first episode, Dr. Chad Briscoe is joined by his guest, Ph.D scientist, Dr. Jim McNally, and they get down to business as the two explore the various nuances in the outstanding work of McNally, how his career in bioanalysis became personal in an unexpected…
In today’s episode, Dr. Chad Briscoe sits down with guest scientist and biomarker expert, Dr. Marianne Fjording (Scientific Officer, BioAgilytix). Marianne and Chad discuss her expertise in biomarkers and EU bioanalysis- including how Denmark became a scientific hub and what fit-for-purpose really means. They also dive into Marianne’s jump from pharma to CRO, a family…